CD19 and plasma cell myeloma: To date, the U.S. Food and Drug Administration (FDA) has approved CD19-targeted CAR T-cells for patients with relapsed/refractory (R/R) leukemia and lymphoma, and B-cell maturation antigen (BCMA)-targeted CAR T-cells for patients with R/R multiple myeloma [1].